These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25365757)

  • 21. New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
    Hussar DA; Wetty DR
    J Am Pharm Assoc (2003); 2015; 55(1):106, 108-10. PubMed ID: 25575154
    [No Abstract]   [Full Text] [Related]  

  • 22. New antiplatelet agent approved.
    Traynor K
    Am J Health Syst Pharm; 2014 Jun; 71(12):977. PubMed ID: 24865749
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiplatelet therapy: Vorapaxar in diabetes and MI.
    Lim GB
    Nat Rev Cardiol; 2015 Apr; 12(4):195. PubMed ID: 25732360
    [No Abstract]   [Full Text] [Related]  

  • 24. Any room left for new antiplatelet agents in acute coronary syndrome?
    Collet JP; Montalescot G
    Eur Heart J; 2013 Jun; 34(23):1699-701. PubMed ID: 23585493
    [No Abstract]   [Full Text] [Related]  

  • 25. Vascular disease: vorapaxar prevents progression of peripheral artery disease.
    Hiatt WR
    Nat Rev Cardiol; 2013 Jul; 10(7):367-8. PubMed ID: 23629438
    [No Abstract]   [Full Text] [Related]  

  • 26. Aspirin in the secondary prevention of cardiovascular disease.
    Parekh AK; Galloway JM; Hong Y; Wright JS
    N Engl J Med; 2013 Jan; 368(3):204-5. PubMed ID: 23323896
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
    Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
    Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet therapy in cardiovascular disease.
    Ahmed SM; O'Leary EL; Innone LA
    Compr Ther; 2010; 36():20-2. PubMed ID: 21229816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual antiplatelet therapy for primary and secondary prevention.
    Mathur AP; Waller AH; Dhruvakumar S; Mazza V; Gerula C; Maher J; Klapholz M; Kaluski E
    Minerva Cardioangiol; 2012 Dec; 60(6):611-28. PubMed ID: 23147438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular pharmacology core reviews: aspirin.
    Gaglia MA; Clavijo L
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):505-13. PubMed ID: 24057863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
    Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
    Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.
    Lièvre M; Cucherat M
    Fundam Clin Pharmacol; 2010 Jun; 24(3):385-91. PubMed ID: 19678849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging antithrombotic drugs for acute coronary syndrome.
    Shimada YJ; Giugliano RP
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):307-18. PubMed ID: 23848430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antiplatelet agents: why they are needed.
    Franchini M; Mannucci PM
    Eur J Intern Med; 2009 Dec; 20(8):733-8. PubMed ID: 19892299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiplatelet agents in secondary prevention of stroke].
    De Gautard G; Perrier A
    Rev Med Suisse; 2014 Oct; 10(446):1902, 1904-7. PubMed ID: 25438372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.